Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Comparative Bioavailability of Rupatadine vs Clarinex in Healthy Subjects
NCT05356143Phase 1Completed
- Sponsor
- Uriach
- Start
- Dec 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rupatadine in allergic rhinitis (AR) (3 arms), sponsored by Uriach. Primary endpoint: Comparative bioavailability of drug products at 3 weeks. Started Dec 2021; status: completed.
02
Drugs
rupatadine
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT05356143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05356143.